These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 27206263)

  • 81. Ranibizumab in retinopathy of prematurity - one-year follow-up of ophthalmic outcomes and two-year follow-up of neurodevelopmental outcomes from the CARE-ROP study.
    Stahl A; Bründer MC; Lagrèze WA; Molnár FE; Barth T; Eter N; Guthoff R; Krohne TU; Pfeil JM;
    Acta Ophthalmol; 2022 Feb; 100(1):e91-e99. PubMed ID: 33742551
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Laser Therapy Versus Anti-VEGF Agents for Treatment of Retinopathy of Prematurity.
    Leskov I; Mukai S
    Int Ophthalmol Clin; 2015; 55(4):81-90. PubMed ID: 26322428
    [No Abstract]   [Full Text] [Related]  

  • 83. Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF).
    Tsai AS; Chou HD; Ling XC; Al-Khaled T; Valikodath N; Cole E; Yap VL; Chiang MF; Chan RVP; Wu WC
    Prog Retin Eye Res; 2022 May; 88():101018. PubMed ID: 34763060
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Ranibizumab: A Review in Retinopathy of Prematurity.
    Lee A; Shirley M
    Paediatr Drugs; 2021 Jan; 23(1):111-117. PubMed ID: 33447937
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
    Han J; Kim SE; Lee SC; Lee CS
    Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy.
    Kuo HK; Sun IT; Chung MY; Chen YH
    Ophthalmologica; 2015; 234(4):211-7. PubMed ID: 26393895
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
    Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
    [No Abstract]   [Full Text] [Related]  

  • 88. Reactivation of retinopathy of prematurity after bevacizumab injection.
    Hu J; Blair MP; Shapiro MJ; Lichtenstein SJ; Galasso JM; Kapur R
    Arch Ophthalmol; 2012 Aug; 130(8):1000-6. PubMed ID: 22491394
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Update on the Use of Anti-VEGF Drugs in the Treatment of Retinopathy of Prematurity.
    Seery CW; Betesh S; Guo S; Zarbin MA; Bhagat N; Wagner RS
    J Pediatr Ophthalmol Strabismus; 2020 Nov; 57(6):351-362. PubMed ID: 33211892
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial.
    Stahl A; Lepore D; Fielder A; Fleck B; Reynolds JD; Chiang MF; Li J; Liew M; Maier R; Zhu Q; Marlow N
    Lancet; 2019 Oct; 394(10208):1551-1559. PubMed ID: 31522845
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Hypotension Associated With Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity.
    Wu LH; Yang YH; Lin CH; Lin YJ; Cheng CL
    Pediatrics; 2016 Feb; 137(2):e20152005. PubMed ID: 26743817
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity.
    Cheng HC; Lee SM; Hsieh YT; Lin PK
    Retina; 2015 Apr; 35(4):660-6. PubMed ID: 25313709
    [TBL] [Abstract][Full Text] [Related]  

  • 93. New insights in diagnosis and treatment for Retinopathy of Prematurity.
    Cernichiaro-Espinosa LA; Olguin-Manriquez FJ; Henaine-Berra A; Garcia-Aguirre G; Quiroz-Mercado H; Martinez-Castellanos MA
    Int Ophthalmol; 2016 Oct; 36(5):751-60. PubMed ID: 26767656
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Very late-onset reactivation of retinopathy of prematurity post anti-VEGF bevacizumab treatment for type 1 ROP: a case report.
    Taylor K; Ghergherehchi L; Rao P; Harper CA; Chang E
    J AAPOS; 2021 Jun; 25(3):180-184. PubMed ID: 33964455
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity.
    Tan H; Blasco P; Lewis T; Ostmo S; Chiang MF; Campbell JP
    Surv Ophthalmol; 2021; 66(5):877-891. PubMed ID: 33667496
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial.
    Mintz-Hittner HA
    Eur J Ophthalmol; 2012; 22(5):685-6. PubMed ID: 22669847
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.
    Hartnett ME
    Clin Perinatol; 2014 Dec; 41(4):925-43. PubMed ID: 25459781
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Intravitreal antivascular endothelial growth factor injection versus laser photocoagulation for retinopathy of prematurity: A meta-analysis of 3,701 eyes.
    Popovic MM; Nichani P; Muni RH; Mireskandari K; Tehrani NN; Kertes PJ
    Surv Ophthalmol; 2021; 66(4):572-584. PubMed ID: 33338470
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Retinopathy of prematurity - therapy. Part 2].
    Prepiaková Z; Tomčíková D; Kostolná B; Gerinec A
    Cesk Slov Oftalmol; 2014 Apr; 70(2):50-4. PubMed ID: 25030312
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
    Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
    J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.